Skip to main content
Premium Trial:

Request an Annual Quote

Celera and Seattle Genetics to Develop Antibody-Based Cancer Therapies

NEW YORK, July 21 (GenomeWeb News) - Celera Genomics and Seattle Genetics will collaborate to discover and develop targeted antibody-based therapies for cancer, the companies said today.


The companies will use Celera's proteomics platform to identify specific cell-surface proteins as antigen targets, and Seattle Genetics will screen against those targets to discover corresponding monoclonal antibodies, or antibodies linked to cell-killing compounds.


Celera and Seattle Genetics will co-fund preclinical and clinical drug development, and share any profits arising from commercialization, the companies said. In addition, either company may opt out of co-development for a particular product and receive royalties on net sales.


Celera will contribute cell-surface antigens identified in ongoing proteomics studies in the areas of pancreatic, lung, colon, and breast cancer.

The Scan

And Back

The New York Times reports that missing SARS-CoV-2 genome sequences are back in a different database.

Lacks Family Hires Attorney

A lawyer for the family of Henrietta Lacks plans to seek compensation from pharmaceutical companies that have used her cancer cells in product development, the Baltimore Sun reports.

For the Unknown

The Associated Press reports that family members are calling on the US military to use new DNA analysis techniques to identify unknown sailors and Marines who were on the USS Arizona.

PLOS Papers on Congenital Heart Disease, COVID-19 Infection Host MicroRNAs, Multiple Malformation Mutations

In PLOS this week: new genes linked to congenital heart disease, microRNAs with altered expression in COVID-19, and more.